HCV Infection: Clinical Trials

3 trials for HCV Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 unknown. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Unknown 1

Follow HCV Infection: new trials by email Literature Review of HCV Infection trials Research Report on HCV Infection

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major
Phase 3UnknownAin Shams University242018-06-112023-03-06
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
E/C/F/TAF, F/R/TAF, LDV/SOF - HIV-1 Infection, HCV Infection
Phase 3CompletedGilead Sciences1502016-04-012018-11-14
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
Peginterferon alfa-2a, ribavirin, amantadine - HCV Infection, Hepatitis C, Chronic
Phase 3CompletedUniversity Hospital, Bordeaux1312001-11-012007-06-13

Narrower conditions

Hepatitis C (3)  ·  Hepatitis C, Chronic (1)  ·  beta-Thalassemia (1)

Broader conditions

Blood-Borne Infections (3)  ·  Communicable Diseases (3)  ·  Digestive System Diseases (3)  ·  Flaviviridae Infections (3)  ·  Hepatitis (3)  ·  Hepatitis, Viral, Human (3)  ·  Infections (3)  ·  Liver Diseases (3)  ·  RNA Virus Infections (3)  ·  Virus Diseases (3)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Chronic Disease (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)

Interventions

ledipasvir, sofosbuvir drug combination (2)  ·  Amantadine (1)  ·  Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Ribavirin (1)  ·  peginterferon alfa-2a (1)

Sponsors

Ain Shams University (1)  ·  Gilead Sciences (1)  ·  University Hospital, Bordeaux (1)

Countries

Egypt (1)  ·  France (1)  ·  Puerto Rico (1)  ·  United States (1)

Top investigators

Manal H El-Sayed, M.D (1)  ·  Patrice Couzigou, Pr (1)

Results publications

PMID 31995556, PMID 34186262

NIH funding

2014 (1)